Telaglenastat + Carboplatin Chemotherapy + Pemetrexed Chemotherapy + Pembrolizumab Immunotherapy + Placebo + Dexamethasone 4 mg
Phase 2TerminatedDevelopment Stage
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Jul 24, 2020 → Feb 9, 2022
About Telaglenastat + Carboplatin Chemotherapy + Pemetrexed Chemotherapy + Pembrolizumab Immunotherapy + Placebo + Dexamethasone 4 mg
Telaglenastat + Carboplatin Chemotherapy + Pemetrexed Chemotherapy + Pembrolizumab Immunotherapy + Placebo + Dexamethasone 4 mg is a phase 2 stage product being developed by Calithera Biosciences for Non-Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04265534. Target conditions include Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04265534 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-Small Cell Lung Cancer